About Irhythm Technologies (NASDAQ:IRTC)
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRTC
CUSIPN/A
Phone415-632-5700
Debt
Debt-to-Equity Ratio0.41%
Current Ratio5.72%
Quick Ratio5.64%
Price-To-Earnings
Trailing P/E Ratio-47.95
Forward P/E Ratio-40.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$98.51 million
Price / Sales14.93
Cash FlowN/A
Price / CashN/A
Book Value$3.46 per share
Price / Book18.02
Profitability
EPS (Most Recent Fiscal Year)($1.30)
Net Income$-29,420,000.00
Net Margins-29.87%
Return on Equity-34.44%
Return on Assets-22.04%
Miscellaneous
Employees575
Outstanding Shares23,590,000
Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions
What is Irhythm Technologies' stock symbol?
Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."
How were Irhythm Technologies' earnings last quarter?
Irhythm Technologies Inc (NASDAQ:IRTC) announced its earnings results on Wednesday, February, 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.13. The firm earned $28.20 million during the quarter, compared to analyst estimates of $26.79 million. Irhythm Technologies had a negative net margin of 29.87% and a negative return on equity of 34.44%. The firm's quarterly revenue was up 50.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.37) EPS. View Irhythm Technologies' Earnings History.
When is Irhythm Technologies' next earnings date?
What price target have analysts set for IRTC?
7 equities research analysts have issued 12-month price targets for Irhythm Technologies' shares. Their forecasts range from $60.00 to $80.00. On average, they anticipate Irhythm Technologies' share price to reach $71.1667 in the next twelve months. View Analyst Ratings for Irhythm Technologies.
What are Wall Street analysts saying about Irhythm Technologies stock?
Here are some recent quotes from research analysts about Irhythm Technologies stock:
- 1. Northland Securities analysts commented, "We note that this was a physician-initiated study and funded by Bardy. Also, it is important to take this study within the context of an initial study which could provide clues for a larger head-head study, providing important clues for the sensitivity & specificity of R-R wave vs. P-wave analysis in ambulatory ECG monitoring." (4/16/2018)
- 2. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (1/3/2018)
- 3. Canaccord Genuity analysts commented, "We expect these data, assuming the read-out of the full study data follows suit (which we expect), will build IRTC’s case with payers, paving the way ultimately for prospective screening with Zio in a brand new, 3- million-patient TAM. While not in our model at all, we think over time, payors will cover Zio for screening of high-risk patients defined by the mSToPs study. We reiterate our BUY rating and $59 price target." (11/14/2017)
Who are some of Irhythm Technologies' key competitors?
Some companies that are related to Irhythm Technologies include Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AngioDynamics (ANGO) and AtriCure (ATRC).
Who are Irhythm Technologies' key executives?
Irhythm Technologies' management team includes the folowing people:
- Mr. Kevin M. King, Pres , CEO & Director (Age 62)
- Mr. Matthew C. Garrett, CFO & Chief Accounting Officer (Age 50)
- Mr. David A. Vort, Exec. VP of Sales (Age 52)
- Dr. Derrick Sung Ph.D., Exec. VP of Strategy and Corp. Devel. (Age 45)
- Ms. Judith C. Lenane RN, MHA, Chief Clinical Officer and Exec. VP of Operations (Age 59)
When did Irhythm Technologies IPO?
(IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Has Irhythm Technologies been receiving favorable news coverage?
News coverage about IRTC stock has been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Irhythm Technologies earned a media sentiment score of 0.24 on Accern's scale. They also assigned headlines about the company an impact score of 46.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Irhythm Technologies?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Irhythm Technologies' stock price today?
One share of IRTC stock can currently be purchased for approximately $62.34.
How big of a company is Irhythm Technologies?
Irhythm Technologies has a market capitalization of $1.49 billion and generates $98.51 million in revenue each year. The company earns $-29,420,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Irhythm Technologies employs 575 workers across the globe.
How can I contact Irhythm Technologies?
Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for Irhythm Technologies (IRTC)
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Irhythm Technologies (NASDAQ:IRTC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Irhythm Technologies in the last 12 months. Their average twelve-month price target is $71.1667, suggesting that the stock has a possible upside of 14.16%. The high price target for IRTC is $80.00 and the low price target for IRTC is $60.00. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.71 | 2.71 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $71.1667 | $71.1667 | $67.6667 | $41.00 |
| Price Target Upside: | 14.16% upside | 10.78% upside | 26.84% upside | 15.88% downside |
Irhythm Technologies (NASDAQ:IRTC) Consensus Price Target History
Irhythm Technologies (NASDAQ:IRTC) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Irhythm Technologies (NASDAQ:IRTC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Irhythm Technologies (NASDAQ IRTC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 98.59%
Irhythm Technologies (NASDAQ IRTC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Vijay K. Lathi | Director | Sell | 114,018 | $66.44 | $7,575,355.92 | |  |
| 3/8/2018 | David A Vort | EVP | Sell | 935 | $67.01 | $62,654.35 | 22,221 | |
| 2/26/2018 | Kevin M King | Insider | Sell | 60,000 | $64.52 | $3,871,200.00 | 201,842 | |
| 2/23/2018 | Raymond W Scott | Director | Sell | 8,499 | $65.55 | $557,109.45 | 8,499 | |
| 2/21/2018 | Vijay K Lathi | Director | Sell | 169,000 | $62.41 | $10,547,290.00 | | |
| 1/5/2018 | Matthew C Garrett | CFO | Sell | 42,910 | $59.17 | $2,538,984.70 | 36,085 | |
| 12/7/2017 | Vijay K. Lathi | Director | Sell | 150,000 | $52.57 | $7,885,500.00 | | |
| 12/5/2017 | Vijay K. Lathi | Director | Sell | 57,430 | $52.41 | $3,009,906.30 | | |
| 12/4/2017 | Matthew C Garrett | CFO | Sell | 1,193 | $55.00 | $65,615.00 | | |
| 11/17/2017 | Vijay K Lathi | Director | Sell | 225,000 | $52.10 | $11,722,500.00 | | |
| 11/6/2017 | Kevin M King | Insider | Sell | 60,000 | $51.85 | $3,111,000.00 | 103,042 | |
| 9/13/2017 | Vijay K Lathi | Director | Sell | 34,613 | $49.51 | $1,713,689.63 | 1,405 | |
| 9/12/2017 | David A. Vort | EVP | Sell | 5,000 | $48.76 | $243,800.00 | | |
| 9/7/2017 | Raymond W Scott | Director | Sell | 8,088 | $48.00 | $388,224.00 | 8,088 | |
| 9/6/2017 | Raymond W Scott | Director | Sell | 4,661 | $48.02 | $223,821.22 | 4,661 | |
| 8/28/2017 | Raymond W Scott | Director | Sell | 12,749 | $45.30 | $577,529.70 | 12,749 | |
| 8/7/2017 | Raymond W. Scott | Director | Sell | 52,903 | $43.59 | $2,306,041.77 | | |
| 7/11/2017 | Kevin M. King | Insider | Sell | 110,000 | $42.08 | $4,628,800.00 | | |
| 7/10/2017 | Matthew C. Garrett | CFO | Sell | 25,086 | $42.06 | $1,055,117.16 | | |
| 6/8/2017 | Synergy Life Science Partners | Major Shareholder | Sell | 350,000 | $37.43 | $13,100,500.00 | | |
| 6/8/2017 | Vijay K Lathi | Director | Sell | 430,624 | $37.59 | $16,187,156.16 | | |
| 5/16/2017 | Vijay K Lathi | Director | Sell | 645,000 | $34.70 | $22,381,500.00 | | |
(Data available from 1/1/2013 forward)
Irhythm Technologies (NASDAQ IRTC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Irhythm Technologies (IRTC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 19 at 9:40 PM |
 | iRhythm Technologies to Report First Quarter Financial Results on May 2, 2018
finance.yahoo.com - April 18 at 4:35 PM |
| Irhythm Technologies' (IRTC) "Hold" Rating Reiterated at Northland Securities
www.americanbankingnews.com - April 16 at 11:39 AM |
| Irhythm Technologies (IRTC) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 14 at 8:37 PM |
| Irhythm Technologies (IRTC) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 12 at 11:21 PM |
| Irhythm Technologies (IRTC) and Its Rivals Head to Head Analysis
www.americanbankingnews.com - April 10 at 5:18 PM |
| iRhythm Technologies Appoints UCLA and Cedars-Sinai Professor C. Noel Bairey Merz, M.D. to its Board of Directors
finance.yahoo.com - April 10 at 4:21 PM |
| Comparing T2 Biosystems (TTOO) & Irhythm Technologies (IRTC)
www.americanbankingnews.com - April 10 at 3:25 PM |
| Irhythm Technologies (IRTC) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 9 at 8:25 AM |
| Brokerages Anticipate Irhythm Technologies Inc (IRTC) Will Announce Quarterly Sales of $28.75 Million
www.americanbankingnews.com - April 9 at 2:16 AM |
| Irhythm Technologies (IRTC) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:36 PM |
| Analysts Expect Irhythm Technologies Inc (IRTC) to Post -$0.42 Earnings Per Share
www.americanbankingnews.com - April 7 at 7:12 PM |
| Head to Head Analysis: Obalon Therapeutics (OBLN) vs. Irhythm Technologies (IRTC)
www.americanbankingnews.com - April 7 at 5:44 PM |
| Irhythm Technologies (IRTC) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM |
| Irhythm Technologies Inc (IRTC) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 10:16 AM |
| Analyzing Valeritas (VLRX) and Irhythm Technologies (IRTC)
www.americanbankingnews.com - April 1 at 11:28 PM |
| Irhythm Technologies (IRTC) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM |
| Irhythm Technologies (IRTC) versus Its Rivals Critical Contrast
www.americanbankingnews.com - March 30 at 3:12 PM |
| How Financially Strong Is iRhythm Technologies Inc (NASDAQ:IRTC)?
finance.yahoo.com - March 30 at 9:43 AM |
| Contrasting Irhythm Technologies (IRTC) & Five Star Senior Living (FVE)
www.americanbankingnews.com - March 27 at 3:20 PM |
| ValuEngine Upgrades Irhythm Technologies (IRTC) to Hold
www.americanbankingnews.com - March 25 at 4:48 PM |
| $28.75 Million in Sales Expected for Irhythm Technologies Inc (IRTC) This Quarter
www.americanbankingnews.com - March 23 at 3:04 AM |
| Analysts Expect Irhythm Technologies Inc (IRTC) Will Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - March 21 at 7:18 PM |
| BidaskClub Lowers Irhythm Technologies (IRTC) to Hold
www.americanbankingnews.com - March 16 at 11:34 PM |
| Irhythm Technologies (IRTC) Earns Hold Rating from Northland Securities
www.americanbankingnews.com - March 14 at 4:40 PM |
| Vijay K. Lathi Sells 114,018 Shares of Irhythm Technologies Inc (IRTC) Stock
www.americanbankingnews.com - March 12 at 7:21 PM |
| Canaccord Genuity Reaffirms "Positive" Rating for Irhythm Technologies (IRTC)
www.americanbankingnews.com - March 12 at 3:28 PM |
| Irhythm Technologies Inc (IRTC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 11 at 10:14 AM |
| Insider Selling: Irhythm Technologies Inc (IRTC) EVP Sells 935 Shares of Stock
www.americanbankingnews.com - March 9 at 3:29 PM |
| IRhythm Technologies Is Breaking Ground In Cardiac Monitoring, Says New Sell-Side Bull
finance.yahoo.com - March 6 at 4:42 PM |
| BMO Capital Markets Initiates Coverage on Irhythm Technologies (IRTC)
www.americanbankingnews.com - March 5 at 8:24 PM |
| Irhythm Technologies Inc (IRTC) Holdings Raised by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 3:35 PM |
| How Do Analysts See iRhythm Technologies Inc (NASDAQ:IRTC) Performing Over The Next Few Years?
finance.yahoo.com - March 3 at 9:34 AM |
| Irhythm Technologies Inc (IRTC) is Next Century Growth Investors LLC's 4th Largest Position
www.americanbankingnews.com - March 2 at 5:58 PM |
| iRhythm Technologies Inc (IRTC) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 2 at 9:28 AM |
| Ascend Capital LLC Purchases 26,839 Shares of Irhythm Technologies Inc (IRTC)
www.americanbankingnews.com - March 2 at 5:04 AM |
| Irhythm Technologies Inc (IRTC) Insider Kevin M. King Sells 60,000 Shares
www.americanbankingnews.com - February 28 at 3:21 PM |
| Irhythm Technologies Inc (IRTC) Director Sells $557,109.45 in Stock
www.americanbankingnews.com - February 26 at 9:08 PM |
| Irhythm Technologies (IRTC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 25 at 5:28 PM |
| Vijay K. Lathi Sells 169,000 Shares of Irhythm Technologies Inc (IRTC) Stock
www.americanbankingnews.com - February 22 at 6:14 PM |
| Free Post Earnings Research Report: Baxter's Quarterly Sales Grew 5%; Adjusted EPS Advanced 12%
finance.yahoo.com - February 22 at 9:25 AM |
| FY2018 EPS Estimates for Irhythm Technologies Inc Cut by Dougherty & Co (IRTC)
www.americanbankingnews.com - February 19 at 5:58 AM |
| Irhythm Technologies Inc (IRTC) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - February 15 at 11:10 PM |
| Irhythm Technologies (IRTC) Stock Rating Reaffirmed by JPMorgan Chase & Co.
www.americanbankingnews.com - February 15 at 11:18 AM |
 | iRhythm Technologies' (IRTC) CEO Kevin King on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 15 at 8:51 AM |
| Irhythm Technologies (IRTC) Announces Quarterly Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - February 14 at 9:12 PM |
| iRhythm Technologies Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Full Year 2018 Financial Outlook
finance.yahoo.com - February 14 at 4:42 PM |
| Irhythm Technologies Inc (IRTC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 14 at 10:38 AM |
| iRhythm Technologies to Present at the RBC Global Healthcare Conference
finance.yahoo.com - February 8 at 9:00 AM |
| Irhythm Technologies (IRTC) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 7 at 4:38 AM |
Irhythm Technologies (NASDAQ:IRTC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Irhythm Technologies (NASDAQ:IRTC) Income Statement, Balance Sheet and Cash Flow Statement
Irhythm Technologies (NASDAQ IRTC) Stock Chart for Friday, April, 20, 2018
Loading chart…
